Across multiple retrospective studies, the most striking differences have been consistently noted between patients with HER2-positive breast cancer (who carry the most favourable prognosis) and those patients with triple-negative breast cancer [14–19]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.